Introduction Executive Summary Muscle spasticity: Overview ● Causes ● Mechanism of Action ● Signs and Symptoms ● Diagnosis ● Disease Management Pipeline Therapeutics ● Comparative Analysis Therapeutic Assessment ● Assessment by Product Type ● Assessment by Stage and Product Type ● Assessment by Route of Administration ● Assessment by Stage and Route of Administration ● Assessment by Molecule Type ● Assessment by Stage and Molecule Type Muscle spasticity – DelveInsight’s Analytical Perspective In-depth Commercial Assessment ● Muscle spasticity companies’ collaborations, Licensing, Acquisition -Deal Value Trends Muscle spasticity Collaboration Deals ● Company-Company Collaborations (Licensing / Partnering) Analysis ● Company-University Collaborations (Licensing / Partnering) Analysis Late Stage Products (Preregistration) ● Comparative Analysis Oltipraz: Pharmaking ● Product Description ● Research and Development ● Product Development Activities Drug profiles in the detailed report….. Mid Stage Products (Phase II) ● Comparative Analysis TERN-101: Terns Pharmaceuticals ● Product Description ● Research and Development ● Product Development Activities Drug profiles in the detailed report….. Early Stage Products (Phase I) ● Comparative Analysis EDP 297: Enanta Pharmaceuticals ● Product Description ● Research and Development ● Product Development Activities Drug profiles in the detailed report….. Preclinical Stage Products ● Comparative Analysis Drug Name: Company Name ● Product Description ● Research and Development ● Product Development Activities Drug profiles in the detailed report….. Inactive Products ● Comparative Analysis Muscle spasticity Key Companies Muscle spasticity Key Products Muscle spasticity- Unmet Needs Muscle spasticity- Market Drivers and Barriers Muscle spasticity- Future Perspectives and Conclusion Muscle spasticity Analyst Views Muscle spasticity Key Companies Appendix

Table 1 Total Products for Muscle spasticity Table 2 Late Stage Products Table 3 Mid Stage Products Table 4 Early Stage Products Table 5 Pre-clinical & Discovery Stage Products Table 6 Assessment by Product Type Table 7 Assessment by Stage and Product Type Table 8 Assessment by Route of Administration Table 9 Assessment by Stage and Route of Administration Table 10 Assessment by Molecule Type Table 11 Assessment by Stage and Molecule Type Table 12 Inactive Products

• Edgewise therapeutics • Osmotica Pharmaceuticals • Ipsen • Revance Therapeutics • Merz Pharmaceuticals GmbH